Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...
Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of scavenger receptor BI as a scavenger of free heme that is essential for protection against hemolysis.

bioRxiv : the preprint server for biology·2026
Same author

Early ApoA-I Treatment Prevents Postsurgical Atherosclerotic Plaque Destabilization.

Circulation research·2026
Same author

Placental Vascular Pathology Associated with Congenital Lymphocytic Choriomeningitis Virus Infection, Philadelphia, Pennsylvania, USA.

Emerging infectious diseases·2026
Same author

Origins of Atlantic Salmon (<i>Salmo salar</i>) Determined Using a Hybridization Assay of Mitochondrial DNA on a Microfluidic Biochip.

Biosensors·2026
Same author

DENND5B disruption results in reduced body fat and increased intestinal fatty acid oxidation by activation of autophagy.

Journal of lipid research·2026
Same author

Lymphocytic Choriomeningitis Virus Seroprevalence among Urban Pregnant Women and Newborns, Philadelphia, Pennsylvania, USA, 2021.

Emerging infectious diseases·2026
Same journal

EDITORIAL INTRODUCTION.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Exploring the role of parathyroid hormone in sarcopenia: A review.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Normocalcemic primary hyperparathyroidism: an update on diagnostic and management challenges.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Prediabetes before pregnancy: implications for risk stratification and research.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Secondary hyperparathyroidism in chronic kidney disease: update on pathophysiology and new treatment targets.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Revisiting the relationship between weight loss and bone health in people living with obesity: insights from the latest evidence.

Current opinion in endocrinology, diabetes, and obesity·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Apolipoprotein A-I mimetics and high-density lipoprotein function.

Scott M Gordon1, William S Davidson

  • 1University of Cincinnati Metabolic Diseases Institute, Cincinnati, Ohio 45237, USA.

Current Opinion in Endocrinology, Diabetes, and Obesity
|January 27, 2012
PubMed
Summary
This summary is machine-generated.

Apolipoprotein A-I (apoA-I) mimetic peptides show promise for treating cardiovascular diseases. These novel therapies exhibit potent cardioprotective effects, including cholesterol efflux and anti-inflammatory properties.

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Related Experiment Videos

Last Updated: May 25, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Biochemistry

Background:

  • Cardiovascular diseases remain a leading cause of mortality worldwide.
  • Apolipoprotein A-I (apoA-I) and high-density lipoproteins (HDLs) play crucial roles in reverse cholesterol transport and possess atheroprotective properties.
  • Developing effective therapeutic strategies to combat cardiovascular diseases is a significant unmet medical need.

Purpose of the Study:

  • To review recent advancements in the development of apolipoprotein A-I (apoA-I) mimetic peptides.
  • To evaluate the potential of these peptides as a novel treatment for cardiovascular diseases.
  • To explore the cardioprotective mechanisms and therapeutic potential of apoA-I mimetic peptides.

Main Methods:

  • Literature review of recently published studies on apoA-I mimetic peptides.
  • Analysis of preclinical and clinical data investigating the efficacy and safety of these peptides.
  • Examination of research identifying structural features and operational mechanisms of apoA-I mimetics.

Main Results:

  • ApoA-I mimetic peptides demonstrate significant cardioprotective features, comparable or superior to native apoA-I and HDLs.
  • These peptides effectively facilitate cholesterol efflux from cells and exhibit anti-inflammatory and antioxidative properties.
  • Emerging evidence highlights the potential role of the intestine in the mechanism of action of these peptides.

Conclusions:

  • Significant progress has been made in the field of apoA-I mimetic peptide therapy.
  • These peptides hold substantial potential for treating cardiovascular diseases.
  • ApoA-I mimetic peptides may also be beneficial for other conditions associated with chronic inflammation and oxidation.